CPT1A and non-small cell lung carcinoma: Emerging agents targeting metabolic pathways, such as CPT1A (carnitine palmitoyltransferase 1A) inhibitors, have validated ferroptosis‐inducing capacity in NSCLC models by disrupting FAO to potentiate LPO [538].